In an industry poised to exceed $250 billion in the the coming years, there isn’t a better time to review your cloud deals to ensure your company is getting maximum value for its cloud spend. As Ian Barker reports in this article https://betanews.com/2017/11/13/company-cloud-waste/, companies are wasting an enormous amount of money on cloud services. These excess costs can be reduced and even avoided.
Here are some things to think about when entering into cloud-based transactions:
- Size your environment correctly. Make sure your environment is sized correctly. Barker reports that “Forty percent of [cloud-based application] instances are sized larger than is required for the workload and could be resized — and therefore made cheaper — without impacting performance of the application.” An environment that is larger than your business needs results in wasted spend. A key benefit of cloud-based applications is the flexibility to re-size your environment periodically. Ensure that your contracts permit this and spend the time to periodically audit your environment to ensure you are using what you have — if you need more, ramp up, and if you have too much, control your cloud costs by scaling down.
- Turn them off! How many of your virtual machines run 24X7 (even though they aren’t being used). As Barker tells us “Turning [your virtual machines] off during times they are not in use can make significant savings. For example, shutting down development instances that are not used at night and at weekends can save 67 percent of the spend.”
- Check your contracts. Typically a cloud computing service will be offered on a “pay as you go” or “pay per use” cost structure (e.g., per virtual machine each hour, per gigabyte of storage each month). Accordingly, your cloud agreements should provide for the ability to both add and remove resources, with a corresponding upward and downward adjustment of the service fees. While the best time for the customer to negotiate rates for incremental use is before signing the agreement, you can periodically re-visit your agreements and engage with suppliers to negotiate more favorable and market-based terms. Additionally, it is fairly common for customers to lock in recurring fees for a period of time (e.g., one to three years) and thereafter a fee escalator based on a pricing index like CPI.
- Watch for additional fees. As part of your cloud transactions ensure that you have identified and included in the fees all potential supplier revenue streams (or, at the very least, if all revenue streams aren’t included in the fees you are paying, you nonetheless know what they are, can anticipate them, and include them in your company’s budgeting process). It is fairly common for providers to attempt to charge additional fees for such things as storage after a certain amount of data, or for software updates.
- Processes matter. Your company’s internal business processes and practices may also be contributing to your cloud computing waste. As Barker reports, “A further cause of waste is a decentralized approach, where departments and business units are able to set up their own cloud instances with no need to go through lengthy approval processes.” Unfortunately, this also means that transaction documents aren’t getting reviewed by lawyers who know what to look for in these types of transactions and know what to negotiate in order to ensure that the company is extracting maximum value out of the relationship and the cloud environment. Implement a process to reduce the ability of business units to enter into unchecked transactions.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.